Hackensack Meridian Health John Theurer Cancer Among First in the World to Adopt RefleXion®X1 Precision Radiation Treatment

John Theurer Cancer Center is 6th site globally to provide BgRT treatment offering a new option for Stage IV cancer care

December 11, 2024

John Theurer Cancer Center at Hackensack University Medical Center will soon launch RefleXion^®X1 BgRT targeted radiation therapy in clinical care. The center is the sixth site worldwide to adopt this precision treatment.

BgRT uses a tumor’s biology to grid radiation beamlets and accommodate subtle movements, such as breathing and muscle flexing, by signaling the treatment to move with the tumor target. This approach spares more healthy tissue than traditional radiation therapies that target a larger circle of healthy tissue around the tumor to accommodate tumor movement.

Using a common tracer and PET imaging, BgRT uses the biology of the tumor to provide constant, live feedback on the tumor’s location to guide the stereotactic radiation delivery. Greater precision may allow delivery of a higher radiation dose to the targeted tumor or allocation of a portion of the allowed radiation dose to a different tumor site. BgRT can accommodate multiple tumors in a single session and offers a new option for metastatic cases.

“We now have a device that treats multiple targets in the same session using the tumor’s biology for guidance,” said Brett Lewis M.D., Ph.D., a radiation oncologist at John Theurer Cancer Center.

The treatment also opens new options to enhance immunotherapy, which can be more successful after the immune system is “primed” by radiation treatment, Dr. Lewis said.

Learn more about our innovations in cancer care.